Market News AIOpen the app

Morgan Stanley lowered its price target for Generate Biomedicines from $22 to $21.

OpinionRead the original at moomoo.com
Neutral

Morgan Stanley lowered its price target from $22 to $21 but kept its Overweight rating. Those mixed views do not show a clear change in Generate Biomedicines' business outlook.

GENB · Generate Biomedicines

AI read · Neutral

The AI's read

The update gives two different signals. Morgan Stanley lowered its price target, but kept its favorable Overweight rating. It reports no new company results or other business change, so the mixed signals do not clearly change Generate Biomedicines' outlook.

Get alerts for GENB

Follow Generate Biomedicines (GENB) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for GENB
Free on the App Store and Google Play, or on the web.